AI in Medical Bills: An Estimate of $942 Million and Contested Conclusions

The Blue Cross Blue Shield Association is credited in the article with estimating possible additional costs of 942 million dollars in 2023–2025 associated with AI in medical billing. Without a primary source and independent verification, this amount cannot be considered established harm. The available materials also contain no data that would make it possible to verify the calculation methodology.

What the Blue Cross Blue Shield Association Is Credited with Estimating

The source material claims, without citing a primary source, that the association linked part of the increase in healthcare costs to algorithms that help code treatment and review bills. The accuracy of this attribution, the association’s conclusions, and the data on which they are based cannot be verified. This remains an unsubstantiated account of a position attributed to the association.

The article attributes a sum of 942 million dollars to the period 2023–2025 and describes it as possible additional costs. This does not confirm that hospitals received precisely that amount in addition to payment for services provided. The available text refers to billing-related costs, not verified payments to specific healthcare organizations.

It is necessary to distinguish between rising bills, the possible influence of algorithms on how they are prepared, and a causal relationship between these phenomena. The information provided is insufficient to establish what share of the additional costs arose because of AI or to confirm the conclusions attributed to the association.

How AI Is Used to Prepare and Review Bills

The source material claims that hospitals use AI to analyze medical documents and prepare bills. According to this description, the algorithm identifies diagnoses and other information in records for coding services. There is no primary source, so it is impossible to verify how widely such tools are used or how the process works at specific facilities. The result of automated analysis, by itself, does not confirm that the information on a bill is supported by the documentation.

It also states that insurers use tools to review bills, find errors, and identify possible overbilling. This describes the presumed role of such systems, not verified information about their use by every insurer. The fact of automation itself does not show which items an insurer accepts or disputes.

Automated analysis does not confirm that a bill was paid. To assess a specific item, it must be compared with the medical documentation and the care provided. In particular, it is important to verify whether the diagnosis reflects the patient’s condition and is related to the treatment.

Why Secondary Diagnoses May Have Become a Source of Discrepancies

The article claims that about 70% of the additional costs identified in the study were associated with secondary diagnoses found through analysis of medical data. This figure and interpretation are presented as a claim from the source material, not as a confirmed result. Without a primary source, neither the 70% share nor the methodology used to calculate it can be verified. Accordingly, this is an unverified report, not an established metric.

The source material also claims that the association’s materials did not note a comparable increase in care actually provided. This is a separate unverified claim: without the study itself, it is impossible to determine which metrics were compared or which period was used as the basis. Even if the number of diagnoses on bills is increasing while the volume of care is changing differently, these metrics cannot be treated as interchangeable.

The absence of a comparable increase in care does not prove that a recorded diagnosis was unnecessary or that a bill was incorrect. Such a conclusion requires medical records, coding rules, information about services provided, and a description of the method used to compare costs. Without these data, it is impossible to establish whether a specific item was justified.

The “Bots Versus Bots” Model

The article attributes to Abridge medical startup founder Shifrau a description of the situation as a possible technological race of “bots versus bots.” Without a link to a primary source, the accuracy and context of the quotation cannot be verified. Even if the wording was conveyed accurately, it does not prove that hospitals and insurers use identical systems or that reviews are performed exclusively by algorithms.

In the model described, automation helps a hospital process documents and prepare a bill, while helping an insurer find disputed items. If both sides use similar tools, the number of grounds for review may change. But without data on system use and review outcomes, it cannot be concluded that the number of errors, unjustified bills, or payment denials is increasing.

The outcome depends on the documentation, system settings, and review rules. An algorithm may speed up the search for information, but by itself it does not confirm a diagnosis or replace an examination of the specific case.

Why the Cost Estimate Should Be Treated with Caution

The source material characterizes the Blue Cross Blue Shield Association as an organization representing insurers’ interests and participating in a financial dispute with healthcare organizations. The available materials confirm neither this characterization nor the association’s participation in such a dispute. This is an unverified description that cannot be used as an established explanation of its position.

Verifying the amount would require information about which bills and periods were included in the calculation, how the impact of AI was assessed, and what other causes of rising costs were taken into account. The available materials contain no detailed methodology or independent confirmation. This estimate cannot be presented as proven financial harm.

The available information does not establish a causal relationship between the use of AI and all additional costs. The fact that processes coincide over time does not by itself prove that one caused the other. Without study data, it is impossible to determine the contribution of other factors.

How to Evaluate Claims About the Financial Impact of Medical AI

When evaluating claims of this kind, it is necessary to trace the path from the medical record to payment. Changes in coding should be distinguished from changes in the volume of care, and the impact of the algorithm from other factors that may have affected costs. This analysis requires primary data, not merely a retelling of conclusions.

• Clarify exactly what was counted. The total amount of bills, insurer costs, paid claims, and an estimate of possible growth are different metrics.
• Check the source and methodology. Determine who conducted the study, what role that party plays in the financial dispute, and whether the calculation is available.
• Examine secondary diagnoses. Compare the information identified by the algorithm with the medical documentation and the services provided to the patient.
• Separate correlation from causation. An increase in bills during the period when AI was used does not by itself prove that AI caused all or any specific part of the increase.
• Compare billing with the volume of care. Check whether the number and nature of services changed along with the number of diagnoses and the amount of the bills.

What can be concluded from the estimate of 942 million dollars? Only that this amount is attributed to an estimate by the Blue Cross Blue Shield Association. Without a primary source, a complete methodology, and independent confirmation, it remains an unverified estimate.

What Is Known and What Remains Contested

The source material claims that hospitals use AI to analyze documents and issue bills, while insurers use it to review submitted amounts. It also attributes to the Blue Cross Blue Shield Association an estimate of possible additional costs in 2023–2025 and a conclusion about the role of secondary diagnoses. The sources provided are insufficient to verify this information.

The causal relationship, the accuracy of the final amount, and the interpretation of diagnoses identified by the algorithm in the documents have not been confirmed. Until these issues are checked against primary data, it is accurate to speak of unverified claims attributed to the association, not of proven harm amounting to 942 million dollars.